Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 10742 participants.
Also called NCT06468202
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 10,742 participants
- Registry
-
NCT06468202
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06468202. Randomized; quadruple masking; primary purpose prevention. Start 2024-10-18 (actual); primary completion 2029-01-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
- Acronym
- ASPIRIN
- Condition
- Hypertensive Disorders of Pregnancy
- Condition
- Preeclampsia
- Condition
- Gestational Hypertension
- Intervention (Drug)
- Aspirin 81 mg
- Intervention (Drug)
- Aspirin 162 mg
- Lead sponsor
- Ohio State University
- Collaborator
- Patient-Centered Outcomes Research Institute
- Collaborator
- Northwestern University
- Collaborator
- Preeclampsia Foundation
Record details
- Record id
cardio:ct-nct06468202- Content hash
dbaabca0c9e6b010e292a6bddfa1a6661c76512c9e301a5af7f77b12bc877bcf